Clinical Trials to Assess the Efficacy and Safety of HLIM
NCT ID: NCT03827590
Last Updated: 2019-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
487 participants
INTERVENTIONAL
2018-11-29
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients
NCT03334916
The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients
NCT06411925
Efficacy and Safety of AG2001 in Patients With Acute Bronchitis
NCT07198347
Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher
NCT01416480
Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis
NCT03489837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HLIM
HLIM+SA160021 Placebo+SA160022 Placebo
Test
three times a day for five days
SA160021
HLIM Placebo+SA160021+SA160022 Placebo
Active Comparator Control 1
three times a day for five days
SA160022
HLIM Placebo+SA160021 Placebo+SA160022
Active Comparator Control 2
three times a day for five days
Placebo
HLIM Placebo+SA160021 Placebo+SA160022 Placebo
Placebo
three times a day for five days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test
three times a day for five days
Active Comparator Control 1
three times a day for five days
Active Comparator Control 2
three times a day for five days
Placebo
three times a day for five days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight more than 11.5 kg
Exclusion Criteria
* Hypertension or Diabetes
* Smoking more than 20 pack-years
2 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SamA Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, Guro-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HLIM(SA16002)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.